(Q82615461)

English

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

scientific article published on 22 January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

based on heuristic

inferred from title

phase III clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

10

object named as

Roy S Herbst

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Vassiliki Papadimitrakopoulou

5

object named as

Vassiliki A Papadimitrakopoulou

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

George R Blumenschein

3

object named as

George R Blumenschein

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Hai T Tran

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Ralph G Zinner

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Yun W Oh

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Edward S Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Charles Lu

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Mubashira Malik

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Bert L Lum

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

22 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

499-505

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20094773%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

https://scigraph.springernature.com/pub.10.1007/s10637-009-9380-z

0 references

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20094773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82615461&oldid=2143416836"